News: AC8 Auscann Group Says Canopy Growth Sold Its 13.2% Interest In Co, page-5

Maybe. But not yet.

Plenty of twists and turns to come. I was looking to buy under 30c but that hasn't happened (yet).

If I was to guess, I would think that the new majority shareholders would want to see progress. Whilst I agree with Ac8's position as a Pharma for long term success, maybe this might push the buttons to reengage some of the dormant licences and generate a bit of revenue in the short term.

The sniff of revenue from AC8 will create a spike towards $1. It was only a few weeks ago it went over $0.50 on the anticipation of revenue via the then financial release.

Couple revenue with movement on the caps and who knows.

All IMO. DYOR.